Izumi M, Iino Y, Yokoe T, Inoue T, Yamada T, Kobayashi I, Andoh T, Yokota T, Iijima T, Morishita Y
Dept. of Surgery, Maebashi Kyoritsu Hospital, Gunma University School of Medicine.
Gan To Kagaku Ryoho. 1994 Feb;21(2):265-8.
A 67-year-old advanced breast cancer patient with multiple bone metastases showed a remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy. Eight course of CTF (cyclophosphamide, THP-adriamycin, 5-fluorouracil) and subsequent 4'-epi-adriamycin were performed for locally advanced breast cancer and multiple bone metastases, but the ulcerated breast cancer enlarged. Then the combination therapy of MIT (10 mg/day) and MPA (1,200 mg/day) was carried out. Seven months after treatment, the ulcerated breast cancer disappeared completely and the serum levels of CA 15-3, TPA and CEA decreased within the normal range. These results suggest that combination therapy with mitoxantrone may well be effective against the anthracycline-resistant breast cancer.
一名67岁的晚期乳腺癌伴多发骨转移患者，在蒽环类药物治疗失败后，对米托蒽醌（MIT）和醋酸甲羟孕酮（MPA）联合治疗表现出显著反应。该患者针对局部晚期乳腺癌和多发骨转移接受了8个疗程的CTF（环磷酰胺、吡柔比星、5-氟尿嘧啶）治疗以及随后的表柔比星治疗，但溃疡性乳腺癌仍增大。随后进行了MIT（10毫克/天）和MPA（1200毫克/天）的联合治疗。治疗7个月后，溃疡性乳腺癌完全消失，血清CA 15-3、组织多肽抗原（TPA）和癌胚抗原（CEA）水平降至正常范围。这些结果表明，米托蒽醌联合治疗可能对耐蒽环类药物的乳腺癌有效。
